Medicine & Life Sciences
aliflurane
8%
Biomarkers
9%
Circulating Neoplastic Cells
37%
Cisplatin
10%
Clinical Trials
22%
Cohort Studies
6%
Confidence Intervals
14%
Cryopreservation
35%
Demography
6%
Disease Progression
6%
Drug Therapy
17%
Electronic Health Records
13%
Embryonal Carcinoma
8%
Germ Cell and Embryonal Neoplasms
99%
Hispanic Americans
5%
Information Technology
35%
Insurance Coverage
9%
Kidney Neoplasms
68%
Liquid Biopsy
14%
Lymph Node Excision
5%
Neoplasm Metastasis
10%
Neoplasms
27%
Nonseminomatous germ cell tumor
19%
Odds Ratio
11%
Office Visits
8%
Oncologists
33%
Orchiectomy
45%
Patient Care
25%
Patient Safety
10%
Physicians
5%
Private Hospitals
12%
Progression-Free Survival
13%
Quality of Life
13%
Radiation
5%
Radiosurgery
100%
Radiotherapy
20%
Recurrence
20%
Renal Cell Carcinoma
83%
Safety
8%
Safety-net Providers
91%
Spermatozoa
28%
Survival
12%
Telemedicine
33%
Telephone
6%
Teratoma
34%
Tertiary Care Centers
42%
Testicular Neoplasms
68%
Therapeutics
20%
Tumor Biomarkers
7%
Workflow
6%
Social Sciences
access to patients
8%
clinician
5%
electronics
8%
group membership
5%
health
5%
insurance coverage
7%
scenario
8%
telephone
11%
video
17%
workflow
6%